Finally, we show that this dependence on IL-3/JAK/STAT signaling allowed for targeting of RUNX1-deficient cells using JAK inhibitors in both RUNX1-KO HSPCs and primary AML patient samples. This evidence concerns the gene IL3 and acute myeloid leukemia.